G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $825,489 | -32.7% | 573,256 | +16.3% | 0.01% | -28.6% |
| Q2 2023 | $1,227,012 | +61.6% | 492,776 | +74.0% | 0.01% | +40.0% |
| Q1 2023 | $759,070 | +50.2% | 283,235 | +204.4% | 0.01% | +66.7% |
| Q4 2022 | $505,240 | -60.5% | 93,046 | -9.2% | 0.00% | -70.0% |
| Q3 2022 | $1,280,000 | -36.2% | 102,518 | -74.8% | 0.01% | -37.5% |
| Q2 2022 | $2,006,000 | +732.4% | 406,064 | +3595.2% | 0.02% | +700.0% |
| Q2 2021 | $241,000 | -74.5% | 10,989 | -72.0% | 0.00% | -71.4% |
| Q1 2021 | $945,000 | -59.0% | 39,286 | -69.3% | 0.01% | -65.0% |
| Q4 2020 | $2,304,000 | +61.8% | 128,083 | +3.9% | 0.02% | +33.3% |
| Q3 2020 | $1,424,000 | +4.3% | 123,299 | +119.2% | 0.02% | 0.0% |
| Q2 2020 | $1,365,000 | +273.0% | 56,258 | +69.5% | 0.02% | +200.0% |
| Q1 2020 | $366,000 | +47.0% | 33,188 | +252.1% | 0.01% | +150.0% |
| Q4 2019 | $249,000 | – | 9,427 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |